{"schema_version":"secwatch.filing_event.v1","accession":"0000773840-24-000102","form_type":"8-K","ticker":"HON","cik":"0000773840","company_name":"HONEYWELL INTERNATIONAL INC","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.005242+00:00","generated_at":"2026-05-29T12:25:47.873745+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Honeywell signs $17B Bombardier deal, cuts FY 2024 guidance","bullets":["Strategic agreement with Bombardier for avionics, HTF7K engines, JetWave X satcom; $17B revenue potential over life.","All legacy pending litigation between companies resolved.","FY 2024 guidance cut: sales now $38.2–$38.4B (down $0.4B); adjusted EPS $9.68–$9.78 (down $0.47).","Q4 2024 adjusted EPS guided $2.26–$2.36, down 16%–12% YoY vs prior guidance of 1%–5% growth.","Segment margin guidance cut 80 bps to 22.6%–22.7%; free cash flow now $4.6–$4.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0000773840-24-000102","json":"https://secwatch.observer/filing/0000773840-24-000102.json","markdown":"https://secwatch.observer/filing/0000773840-24-000102.md","text":"https://secwatch.observer/filing/0000773840-24-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/773840/000077384024000102/0000773840-24-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/773840/000077384024000102/hon-20241202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:25:47.873745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001213900-26-063832","ticker":"USAR","company_name":"USA Rare Earth, Inc.","filed_at":"2026-06-02T13:14:30+00:00","headline":"USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity","event_type":"other_material","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063832","json":"https://secwatch.observer/filing/0001213900-26-063832.json","markdown":"https://secwatch.observer/filing/0001213900-26-063832.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/0001213900-26-063832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/ea0293127-8k_usarare.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026761","ticker":"CELC","company_name":"Celcuity Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026761","json":"https://secwatch.observer/filing/0001493152-26-026761.json","markdown":"https://secwatch.observer/filing/0001493152-26-026761.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/0001493152-26-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069246","ticker":"SHAK","company_name":"Shake Shack Inc.","filed_at":"2026-06-02T12:06:18+00:00","headline":"Shake Shack cuts Q2 revenue guidance to $415-420M, same-shack sales to 2.5-3.0%","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069246","json":"https://secwatch.observer/filing/0001104659-26-069246.json","markdown":"https://secwatch.observer/filing/0001104659-26-069246.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620533/000110465926069246/0001104659-26-069246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620533/000110465926069246/tm2616608d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069206","ticker":"RZLT","company_name":"Rezolute, Inc.","filed_at":"2026-06-02T11:05:59+00:00","headline":"Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069206","json":"https://secwatch.observer/filing/0001104659-26-069206.json","markdown":"https://secwatch.observer/filing/0001104659-26-069206.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/0001104659-26-069206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0002007587-26-000071","ticker":"AII","company_name":"American Integrity Insurance Group, Inc.","filed_at":"2026-06-01T20:31:10+00:00","headline":"American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002007587-26-000071","json":"https://secwatch.observer/filing/0002007587-26-000071.json","markdown":"https://secwatch.observer/filing/0002007587-26-000071.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/0002007587-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/aii-20260601.htm"},"side_by_side_evidence":null},{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001570585-26-000084","ticker":"LBTYA","company_name":"Liberty Global Ltd.","filed_at":"2026-06-01T20:07:09+00:00","headline":"Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001570585-26-000084","json":"https://secwatch.observer/filing/0001570585-26-000084.json","markdown":"https://secwatch.observer/filing/0001570585-26-000084.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570585/000157058526000084/0001570585-26-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570585/000157058526000084/lbtya-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}